Michael Wong

List of Publications by Year
in descending order

105 papers	6,438 citations	71102 41 h-index	69250 77 g-index
105 all docs	105 docs citations	105 times ranked	6265 citing authors

#	Article	IF	Citations
1	Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances. Biomedical Journal, 2022, 45, 27-37.	3.1	13
2	Illuminating Seizures: Combined Optical and Electrophysiological Recording Techniques Provide Novel Insights Into Seizure Dynamics. Epilepsy Currents, 2022, 22, 153575972110536.	0.8	0
3	Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy Research, 2022, 181, 106890.	1.6	10
4	Commentary on â€œThe epileptogenic zone in children with tuberous sclerosis complex is characterized by prominent features of focal cortical dysplasiaâ€. Epilepsia Open, 2022, , .	2.4	0
5	Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. Brain Pathology, 2021, 31, e12949.	4.1	11
6	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology, 2021, 78, 285.	9.0	139
7	Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex. Neurobiology of Disease, 2020, 134, 104615.	4.4	21
8	Modifying genetic epilepsies â€“ Results from studies on tuberous sclerosis complex. Neuropharmacology, 2020, 166, 107908.	4.1	31
9	Astrocyte deletion of Î±2-Na/K ATPase triggers episodic motor paralysis in mice via a metabolic pathway. Nature Communications, 2020, 11, 6164.	12.8	23
10	Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?. Epilepsia, 2020, 61, 359-386.	5.1	57
11	Early developmental electroencephalography abnormalities, neonatal seizures, and induced spasms in a mouse model of tuberous sclerosis complex. Epilepsia, 2020, 61, 879-891.	5.1	10
12	Mild chronic perturbation of inhibition severely alters hippocampal function. Scientific Reports, 2019, 9, 16431.	3.3	4
13	Adipose tissue NAD ⁺ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23822-23828.	7.1	48
14	Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice. Cell Metabolism, 2019, 30, 329-342.e5.	16.2	239
15	Cerebral aquaporin-4 expression is independent of seizures in tuberous sclerosis complex. Neurobiology of Disease, 2019, 129, 93-101.	4.4	5
16	The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex. Journal of Neurodevelopmental Disorders, 2019, 11, 30.	3.1	38
17	Neurofibromatosis type 1 (<i>Nf1</i>)â€mutant mice exhibit increased sleep fragmentation. Journal of Sleep Research, 2019, 28, e12816.	3.2	11
18	Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity. Oncotarget, 2019, 10, 5824-5834.	1.8	18

#	Article	IF	Citations
19	mTORopathies as Signaling Pathway Disorders in Developmental Epilepsies. , 2019, , 327-347.		0
20	Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats. Annals of Clinical and Translational Neurology, 2018, 5, 138-146.	3.7	59
21	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€"</scp>associated refractory seizures. Epilepsia, 2018, 59, 1188-1197.	5.1	41
22	Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development. Journal of Child Neurology, 2018, 33, 55-63.	1.4	17
23	Longitudinal analysis of developmental changes in electroencephalography patterns and sleep-wake states of the neonatal mouse. PLoS ONE, 2018, 13, e0207031.	2.5	39
24	Characterization of a Mouse Model of BÃ¶rjeson-Forssman-Lehmann Syndrome. Cell Reports, 2018, 25, 1404-1414.e6.	6.4	19
25	The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex. Epilepsia, 2018, 59, 1796-1806.	5.1	29
26	Epilepsy treatment patterns among patients with tuberous sclerosis complex. Journal of the Neurological Sciences, 2018, 391, 104-108.	0.6	19
27	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	1.6	54
28	The mTOR pathway in treatment of epilepsy: a clinical update. Future Neurology, 2018, 13, 49-58.	0.5	47
29	Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an ageâ€dependent manner. Epilepsia, 2017, 58, 2053-2063.	5.1	24
30	Rapamycin Attenuates Acute Seizure-induced Astrocyte Injury in Mice in Vivo. Scientific Reports, 2017, 7, 2867.	3.3	22
31	Tumor suppressor Tsc1 is a new Hsp90 coâ€chaperone that facilitates folding of kinase and nonâ€kinase clients. EMBO Journal, 2017, 36, 3650-3665.	7.8	64
32	Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. Journal of Child Neurology, 2017, 32, 1092-1098.	1.4	31
33	Tuberous Sclerosis and Other mTORopathies. , 2017, , 797-810.		1
34	In Vivo Two-Photon Imaging of Astrocytes in GFAP-GFP Transgenic Mice. PLoS ONE, 2017, 12, e0170005.	2.5	25
35	2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. Epilepsy Currents, 2016, 16, 187-191.	0.8	11
36	Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex. Epilepsia, 2016, 57, 1317-1325.	5.1	37

#	Article	IF	Citations
37	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
38	Commentary: mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. Epilepsia, 2016, 57, 1349-1350.	5.1	1
39	Rapamycin prevents acute dendritic injury following seizures. Annals of Clinical and Translational Neurology, 2016, 3, 180-190.	3.7	8
40	Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex. Epilepsia, 2016, 57, 1443-1449.	5.1	27
41	mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology. Current Neurology and Neuroscience Reports, 2016, 16, 102.	4.2	24
42	Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy. Expert Review of Neurotherapeutics, 2016, 16, 437-447.	2.8	10
43	Genetic animal models of malformations of cortical development and epilepsy. Journal of Neuroscience Methods, 2016, 260, 73-82.	2.5	38
44	Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex. Epilepsia, 2015, 56, 1088-1097.	5.1	42
45	Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats. PLoS ONE, 2015, 10, e0135256.	2.5	20
46	Tuber-Less Models of Tuberous Sclerosis Still Provide Insights into Epilepsy. Epilepsy Currents, 2015, 15, 129-130.	0.8	2
47	Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex. Neurobiology of Disease, 2015, 80, 70-79.	4.4	48
48	mTOR Inhibition in Epilepsy: Rationale and Clinical Perspectives. CNS Drugs, 2015, 29, 91-99.	5.9	80
49	mTOR Strikes Again: Mtorc1 Activation Causes Epilepsy Independent of Overt Pathological Changes. Epilepsy Currents, 2014, 14, 41-43.	0.8	6
50	Clinical Neurogenetics. Neurologic Clinics, 2013, 31, 891-913.	1.8	4
51	Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Experimental Neurology, 2013, 244, 22-26.	4.1	46
52	A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Review of Neurotherapeutics, 2013, 13, 657-669.	2.8	103
53	â€œTORâ€•ing down the Dentate Gate in Temporal Lobe Epilepsy. Epilepsy Currents, 2013, 13, 260-261.	0.8	0
54	Cleaning up Epilepsy and Neurodegeneration: The Role of Autophagy in Epileptogenesis. Epilepsy Currents, 2013, 13, 177-178.	0.8	16

#	Article	IF	Citations
55	Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex. PLoS ONE, 2013, 8, e57445.	2.5	86
56	Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases. Biomedical Journal, 2013, 36, 40.	3.1	141
57	Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury. PLoS ONE, 2013, 8, e64078.	2.5	141
58	mTOR as a potential treatment target for epilepsy. Future Neurology, 2012, 7, 537-545.	0.5	44
59	Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures. Epilepsia, 2012, 53, 2026-2033.	5.1	20
60	Tuberous sclerosis and epilepsy: Role of astrocytes. Glia, 2012, 60, 1244-1250.	4.9	40
61	Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy. Current Neurology and Neuroscience Reports, 2012, 12, 410-418.	4.2	50
62	Pentylenetetrazoleâ€induced seizures cause acute, but not chronic, mTOR pathway activation in rat. Epilepsia, 2012, 53, 506-511.	5.1	76
63	Brief seizures cause dendritic injury. Neurobiology of Disease, 2012, 45, 348-355.	4.4	40
64	Video-EEG Monitoring Methods for Characterizing Rodent Models of Tuberous Sclerosis and Epilepsy. Methods in Molecular Biology, 2012, 821, 373-391.	0.9	10
65	Enhanced Epidermal Growth Factor, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor Expression in Tuberous Sclerosis Complex. American Journal of Pathology, 2011, 178, 296-305.	3.8	34
66	Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neuroscience Letters, 2011, 497, 231-239.	2.1	64
67	Rapamycin for Treatment of Epilepsy: Antiseizure, Antiepileptogenic, Both, or Neither?. Epilepsy Currents, 2011, 11, 66-68.	0.8	21
68	The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia, 2011, 52, e7-e11.	5.1	223
69	Epilepsy is both a symptom and a disease: A proposal for a two-tiered classification system. Epilepsia, 2011, 52, 1201-1203.	5.1	13
70	Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex. Human Molecular Genetics, 2011, 20, 445-454.	2.9	191
71	Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiology of Disease, 2010, 37, 764-771.	4.4	70
72	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia, 2010, 51, 27-36.	5.1	183

#	Article	IF	Citations
73	mTOR and epileptogenesis in developmental brain malformations. Epilepsia, 2010, 51, 72-72.	5.1	7
74	Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): A double-edged sword?. Cell Cycle, 2010, 9, 2281-2285.	2.6	31
75	Pathophysiology of Developmental Epilepsies. , 2010, , 103-119.		0
76	The Mammalian Target of Rapamycin Signaling Pathway Mediates Epileptogenesis in a Model of Temporal Lobe Epilepsy. Journal of Neuroscience, 2009, 29, 6964-6972.	3.6	467
77	Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex. Neurobiology of Disease, 2009, 34, 291-299.	4.4	76
78	Animal models of focal cortical dysplasia and tuberous sclerosis complex: Recent progress toward clinical applications. Epilepsia, 2009, 50, 34-44.	5.1	40
79	Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Molecular and Cellular Pharmacology, 2009, 1, 124-129.	1.7	36
80	Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Annals of Neurology, 2008, 63, 444-453.	5.3	563
81	Mechanisms of Epileptogenesis in Tuberous Sclerosis Complex and Related Malformations of Cortical Development with Abnormal Glioneuronal Proliferation. Epilepsia, 2008, 49, 8-21.	5.1	155
82	Stabilizing dendritic structure as a novel therapeutic approach for epilepsy. Expert Review of Neurotherapeutics, 2008, 8, 907-915.	2.8	25
83	Kainate Seizures Cause Acute Dendritic Injury and Actin Depolymerization<i>In Vivo</i>. Journal of Neuroscience, 2007, 27, 11604-11613.	3.6	153
84	The Natural History and Treatment of Epilepsy in a Murine Model of Tuberous Sclerosis. Epilepsia, 2007, 48, 1470-1476.	5.1	58
85	The Utility of Tuberless Models of Tuberous Sclerosis. Epilepsia, 2007, 48, 1629-1630.	5.1	8
86	Hippocampal seizures cause depolymerization of filamentous actin in neurons independent of acute morphological changes. Brain Research, 2007, 1143, 238-246.	2.2	20
87	Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiology of Disease, 2007, 25, 150-162.	4.4	155
88	Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiology of Disease, 2007, 28, 184-196.	4.4	116
89	CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Molecular Therapy, 2006, 13, 538-547.	8.2	125
90	Epileptogenesis and Reduced Inward Rectifier Potassium Current in Tuberous Sclerosis Complex-1-Deficient Astrocytes. Epilepsia, 2005, 46, 1871-1880.	5.1	113

#	Article	IF	Citations
91	Transient decrease in F-actin may be necessary for translocation of proteins into dendritic spines. European Journal of Neuroscience, 2005, 22, 2995-3005.	2.6	74
92	Advances in the Pathophysiology of Developmental Epilepsies. Seminars in Pediatric Neurology, 2005, 12, 72-87.	2.0	19
93	In vivo imaging of dendritic spines during electrographic seizures. Annals of Neurology, 2005, 58, 888-898.	5.3	48
94	Modulation of dendritic spines in epilepsy: Cellular mechanisms and functional implications. Epilepsy and Behavior, 2005, 7, 569-577.	1.7	67
95	Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Annals of Neurology, 2003, 54, 251-256.	5.3	176
96	Analysis of Cerebrospinal Fluid Glial Fibrillary Acidic Protein after Seizures in Children. Epilepsia, 2003, 44, 1455-1458.	5.1	37
97	An animal model of generalized nonconvulsive status epilepticus: immediate characteristics and long-term effects. Experimental Neurology, 2003, 183, 87-99.	4.1	40
98	Cerebrospinal Fluid Neuron-Specific Enolase Following Seizures in Children: Role of Etiology. Journal of Child Neurology, 2002, 17, 261-264.	1.4	19
99	Astrocyte-specificTSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Annals of Neurology, 2002, 52, 285-296.	5.3	330
100	Infantile spasms. Pediatric Neurology, 2001, 24, 89-98.	2.1	107
101	Developmental characteristics of epileptiform activity in immature rat neocortex: a comparison of four in vitro seizure models. Developmental Brain Research, 2001, 128, 113-120.	1.7	45
102	Motor benefit from levodopa in spastic quadriplegic cerebral palsy. Annals of Neurology, 2000, 47, 662-665.	5.3	35
103	Cyclosporine Induces Epileptiform Activity in an In Vitro Seizure Model. Epilepsia, 2000, 41, 271-276.	5.1	27
104	Rapid Cooling Aborts Seizureâ€Like Activity in Rodent Hippocampalâ€Entorhinal Slices. Epilepsia, 2000, 41, 1241-1248.	5.1	63
105	Linkage analysis of candidate myelin genes in familial multiple sclerosis. Neurogenetics, 1999, 2, 155-162.	1.4	21